FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056588555> ?p ?o ?g. }

• W2056588555 endingPage "188" @default.
• W2056588555 startingPage "1" @default.
• W2056588555 abstract "Background The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial aimed to determine whether or not oral Δ 9 -tetrahydrocannabinol (Δ 9 -THC) slowed the course of progressive multiple sclerosis (MS); evaluate safety of cannabinoid administration; and, improve methods for testing treatments in progressive MS. Objectives There were three objectives in the CUPID study: (1) to evaluate whether or not Δ 9 -THC could slow the course of progressive MS; (2) to assess the long-term safety of Δ 9 -THC; and (3) to explore newer ways of conducting clinical trials in progressive MS. Design The CUPID trial was a randomised, double-blind, placebo-controlled, parallel-group, multicentre trial. Patients were randomised in a 2 : 1 ratio to Δ 9 -THC or placebo. Randomisation was balanced according to Expanded Disability Status Scale (EDSS) score, study site and disease type. Analyses were by intention to treat, following a pre-specified statistical analysis plan. A cranial magnetic resonance imaging (MRI) substudy, Rasch measurement theory (RMT) analyses and an economic evaluation were undertaken. Setting Twenty-seven UK sites. Participants Adults aged 18–65 years with primary or secondary progressive MS, 1-year evidence of disease progression and baseline EDSS 4.0–6.5. Interventions Oral Δ 9 -THC (maximum 28 mg/day) or matching placebo. Assessment visits Three and 6 months, and then 6-monthly up to 36 or 42 months. Main outcome measures Primary outcomes were time to EDSS progression, and change in Multiple Sclerosis Impact Scale-29 version 2 (MSIS-29v2) 20-point physical subscale (MSIS-29phys) score. Various secondary patient- and clinician-reported outcomes and MRI outcomes were assessed. RMT analyses examined performance of MS-specific rating scales as measurement instruments and tested for a symptomatic or disease-modifying treatment effect. Economic evaluation estimated mean incremental costs and quality-adjusted life-years (QALYs). Results Effectiveness – recruitment targets were achieved. Of the 498 randomised patients (332 to active and 166 to placebo), 493 (329 active and 164 placebo) were analysed. Primary outcomes: no significant treatment effect; hazard ratio EDSS score progression (active : placebo) 0.92 [95% confidence interval (CI) 0.68 to 1.23]; and estimated between-group difference in MSIS-29phys score (active–placebo) –0.9 points (95% CI –2.0 to 0.2 points). Secondary clinical and MRI outcomes: no significant treatment effects. Safety – at least one serious adverse event: 35% and 28% of active and placebo patients, respectively. RMT analyses – scale evaluation: MSIS-29 version 2, MS Walking Scale-12 version 2 and MS Spasticity Scale-88 were robust measurement instruments. There was no clear symptomatic or disease-modifying treatment effect. Economic evaluation – estimated mean incremental cost to NHS over usual care, over 3 years £27,443.20 per patient. No between-group difference in QALYs. Conclusions The CUPID trial failed to demonstrate a significant treatment effect in primary or secondary outcomes. There were no major safety concerns, but unwanted side effects seemed to affect compliance. Participants were more disabled than in previous studies and deteriorated less than expected, possibly reducing our ability to detect treatment effects. RMT analyses supported performance of MS-specific rating scales as measures, enabled group- and individual person-level examination of treatment effects, but did not influence study inferences. The intervention had significant additional costs with no improvement in health outcomes; therefore, it was dominated by usual care and not cost-effective. Future work should focus on determining further factors to predict clinical deterioration, to inform the development of new studies, and modifying treatments in order to minimise side effects and improve study compliance. The absence of disease-modifying treatments in progressive MS warrants further studies of the cannabinoid pathway in potential neuroprotection. Trial registration Current Controlled Trials ISRCTN62942668. Funding The National Institute for Health Research Health Technology Assessment programme, the Medical Research Council Efficacy and Mechanism Evaluation programme, Multiple Sclerosis Society and Multiple Sclerosis Trust. The report will be published in full in Health Technology Assessment ; Vol. 19, No. 12. See the NIHR Journals Library website for further project information." @default.
• W2056588555 created "2016-06-24" @default.
• W2056588555 creator A5008883455 @default.
• W2056588555 creator A5010629095 @default.
• W2056588555 creator A5013281427 @default.
• W2056588555 creator A5025078599 @default.
• W2056588555 creator A5026566731 @default.
• W2056588555 creator A5028517466 @default.
• W2056588555 creator A5041016511 @default.
• W2056588555 creator A5046539019 @default.
• W2056588555 creator A5062598432 @default.
• W2056588555 creator A5083168810 @default.
• W2056588555 creator A5085218809 @default.
• W2056588555 creator A5088428839 @default.
• W2056588555 date "2015-02-01" @default.
• W2056588555 modified "2023-10-18" @default.
• W2056588555 title "The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis" @default.
• W2056588555 cites W1628226928 @default.
• W2056588555 cites W1801725150 @default.
• W2056588555 cites W1965976393 @default.
• W2056588555 cites W1994222210 @default.
• W2056588555 cites W1996146145 @default.
• W2056588555 cites W2022463984 @default.
• W2056588555 cites W2028942474 @default.
• W2056588555 cites W2031114852 @default.
• W2056588555 cites W2046941822 @default.
• W2056588555 cites W2051039162 @default.
• W2056588555 cites W2063923378 @default.
• W2056588555 cites W2067962939 @default.
• W2056588555 cites W2071782474 @default.
• W2056588555 cites W2105490558 @default.
• W2056588555 cites W2105601238 @default.
• W2056588555 cites W2119629949 @default.
• W2056588555 cites W2134843796 @default.
• W2056588555 cites W2140180096 @default.
• W2056588555 cites W2143488726 @default.
• W2056588555 cites W2153372855 @default.
• W2056588555 cites W2169233645 @default.
• W2056588555 cites W4206439534 @default.
• W2056588555 cites W4210933644 @default.
• W2056588555 doi "https://doi.org/10.3310/hta19120" @default.
• W2056588555 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4781163" @default.
• W2056588555 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25676540" @default.
• W2056588555 hasPublicationYear "2015" @default.
• W2056588555 type Work @default.
• W2056588555 sameAs 2056588555 @default.
• W2056588555 citedByCount "51" @default.
• W2056588555 countsByYear W20565885552015 @default.
• W2056588555 countsByYear W20565885552016 @default.
• W2056588555 countsByYear W20565885552017 @default.
• W2056588555 countsByYear W20565885552018 @default.
• W2056588555 countsByYear W20565885552019 @default.
• W2056588555 countsByYear W20565885552020 @default.
• W2056588555 countsByYear W20565885552021 @default.
• W2056588555 countsByYear W20565885552022 @default.
• W2056588555 countsByYear W20565885552023 @default.
• W2056588555 crossrefType "journal-article" @default.
• W2056588555 hasAuthorship W2056588555A5008883455 @default.
• W2056588555 hasAuthorship W2056588555A5010629095 @default.
• W2056588555 hasAuthorship W2056588555A5013281427 @default.
• W2056588555 hasAuthorship W2056588555A5025078599 @default.
• W2056588555 hasAuthorship W2056588555A5026566731 @default.
• W2056588555 hasAuthorship W2056588555A5028517466 @default.
• W2056588555 hasAuthorship W2056588555A5041016511 @default.
• W2056588555 hasAuthorship W2056588555A5046539019 @default.
• W2056588555 hasAuthorship W2056588555A5062598432 @default.
• W2056588555 hasAuthorship W2056588555A5083168810 @default.
• W2056588555 hasAuthorship W2056588555A5085218809 @default.
• W2056588555 hasAuthorship W2056588555A5088428839 @default.
• W2056588555 hasBestOaLocation W20565885551 @default.
• W2056588555 hasConcept C118552586 @default.
• W2056588555 hasConcept C126322002 @default.
• W2056588555 hasConcept C142724271 @default.
• W2056588555 hasConcept C168563851 @default.
• W2056588555 hasConcept C1862650 @default.
• W2056588555 hasConcept C187212893 @default.
• W2056588555 hasConcept C203092338 @default.
• W2056588555 hasConcept C204787440 @default.
• W2056588555 hasConcept C27081682 @default.
• W2056588555 hasConcept C2780640218 @default.
• W2056588555 hasConcept C2780892749 @default.
• W2056588555 hasConcept C535046627 @default.
• W2056588555 hasConcept C71924100 @default.
• W2056588555 hasConceptScore W2056588555C118552586 @default.
• W2056588555 hasConceptScore W2056588555C126322002 @default.
• W2056588555 hasConceptScore W2056588555C142724271 @default.
• W2056588555 hasConceptScore W2056588555C168563851 @default.
• W2056588555 hasConceptScore W2056588555C1862650 @default.
• W2056588555 hasConceptScore W2056588555C187212893 @default.
• W2056588555 hasConceptScore W2056588555C203092338 @default.
• W2056588555 hasConceptScore W2056588555C204787440 @default.
• W2056588555 hasConceptScore W2056588555C27081682 @default.
• W2056588555 hasConceptScore W2056588555C2780640218 @default.
• W2056588555 hasConceptScore W2056588555C2780892749 @default.
• W2056588555 hasConceptScore W2056588555C535046627 @default.
• W2056588555 hasConceptScore W2056588555C71924100 @default.
• W2056588555 hasFunder F4320319990 @default.
• W2056588555 hasFunder F4320320084 @default.

• next